Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...

The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...

The Trump administration has started quietly rehiring some of the U.S. Food and Drug Administration employees it fired last week, according to nine agency sources, shortly after letting them go in a ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug ...

The current state of health services highlights crucial sectors facing disruptions and developments, from US foreign aid freezes affecting disease control supply chains, to the FDA's actions on new ...

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

The Food and Drug Administration announced Friday it had officially declared an end to the nationwide shortage of Ozempic and Wegovy, medications used for diabetes and weight loss. The agency first ...

Novo Nordisk extended a four-day winning streak on Friday, adding 5.18 percent to close at $88.08 apiece as investors cheered ...